Statins and lipid- lowering strategies in cardiorenal patients

Contributions to Nephrology

Volumn 171, Issue , 2011, Pages 143-150

  Bianchi, Stefano ^a   Grimaldi, Daniela ^a   Bigazzi, Roberto ^b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b Ospedali Riuniti di Livorno   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DISEASE COURSE; HUMAN; KIDNEY DISEASE;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LIPIDS;

EID: 79958107533     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000327139     Document Type: Article

References (30)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047. (Pubitemid 350074801)
2. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Gustafson S, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L: US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011;57(Suppl 1):1-526.
3. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16: 489-495. (Pubitemid 41725146)
4. Collins AJ: Cardiovascular mortality in end- stage renal disease. Am J Med Sci 2003;325:163-167. (Pubitemid 36437989)
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 1296-1305.
6. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003;Suppl 87: S24-S31. (Pubitemid 37315504)
7. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20:1048-1056. (Pubitemid 40862092)
8. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal Syndrome. J Am Coll Cardiol 2008;52:1527-1539.
9. McMurray JJ: Chronic kidney disease in patients with cardiac disease: a review of evidence- based treatment. Kidney Int 2005;68:1419-1426. (Pubitemid 43169886)
10. Chan DT, Irish AB, Dogra GK, Watts GF: Dyslipidemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008;196:823-834.
11. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290: F262-272. (Pubitemid 43724980)
12. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007;18:1246-1261. (Pubitemid 46536911)
13. Krane V, Wanner C: The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease. Nephrol Dial Transplant 2002;17(Suppl 11):S23-S27.
14. O'Brien T, Nguyen TT, Zimmerman BR: Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998;73:969-976. (Pubitemid 28467699)
15. Baigent C, Keech A, Kearney PM, et al: Efficacy and safety of cholesterollowering treatment: prospective meta- analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-1278.
16. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-538. (Pubitemid 41725151)
17. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002;13:1918-1927. (Pubitemid 34700618)
18. Nogueira J, Weir M: The unique character of cardiovascular disease in chronic kidney disease and its implication for treatment with lipid- lowering drugs. Clin J Am Soc Nephrol 2007;2:766-785.
19. Strippoli, GF, Navaneethan, SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC: Effects of statins in patients with chronic kidney disease: meta- analysis and metaregression of randomised controlled trials. BMJ 2008;336:645-659.
20. Shepherd J, Kastelein JJ, Vera Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. J Am Coll Cardiol 2008;51:1448-1454. (Pubitemid 351471787)
21. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Steering Committee and Investigators: Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008;83:870-879.
22. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239. (Pubitemid 38924592)
23. SHARP Collaborative Group: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low- density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785-794.
24. Zoja C, Corna D, Camozzi D, Cattaneo D,Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-2908. (Pubitemid 35386909)
25. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a metaanalysis. Kidney Int 2001;59:260-269. (Pubitemid 32055234)
26. Sandhu S, Wiebe N, Fried LF, Tonelli, M: Statins for improving renal outcomes: a meta- analysis. J Am Soc Nephrol 2006;17:2006-2016. (Pubitemid 44036185)
27. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GFM: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;2:CD007784.
28. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2007;2:1131-1139.
29. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-570. (Pubitemid 36278373)
30. Bianchi S, Bigazzi R, Campese VM: Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis 2010;55:671-681.